{"denoms":[{"counts":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"63"}],"units":"Participants"}],"groups":[{"description":"Bortezomib 1.3mg/m\\^2 by IV days 1, 4, 8 \\& 11\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO days 1-4, 9-12, 17-20","id":"BG000","title":"CyBorD (Bortezomib 1.3mg/m^2)"},{"description":"Bortezomib 1.5mg/m\\^2 by IV days 1, 8, 15 \\& 22\n\nCyclophosphamide 300mg/m\\^2 PO days 1, 8, 15 \\& 22\n\nDexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \\& 22","id":"BG001","title":"CyBorD (Bortezomib 1.5mg/m^2)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"38","upperLimit":"75","value":"60"},{"groupId":"BG001","lowerLimit":"36","upperLimit":"70","value":"61"},{"groupId":"BG002","lowerLimit":"36","upperLimit":"75","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"30"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"33"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"24"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"39"}]}],"title":"Canada"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"43"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"20"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameters of Hematologic Response - Serum M-spike >=1g/dL","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"50"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - Serum Immunoglobulin Free Light Chain >=10mg/dL","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"27"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"36"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - Urine M-Spike >= 200mg/24 hours","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"45"}]}],"title":"Yes"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"18"}]}],"title":"No"}],"paramType":"NUMBER","title":"Parameter of Hematologic Response - Bone Marrow Plasma Cells > 30%","unitOfMeasure":"participants"}]}